Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Recruiting in Palo Alto (17 mi)

+63 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Novo Nordisk A/S

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is conducted in the United States of America (USA). The purpose of this study is to test whether Biphasic Insulin Aspart 70/30 twice a day with Metformin improves glycemic control vs. once daily Insulin Glargine with Metformin in subjects with Type 2 Diabetes who are inadequately controlled on basal insulin plus oral anti-diabetic therapy.

Eligibility Criteria

Inclusion Criteria

Type 2 Diabete

Treatment Details

Interventions

• Biphasic Insulin Aspart 70/30 (Insulin)
• Insulin Glargine (Insulin)
• Metformin (Other)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Novo Nordisk Investigational Site Plantation, FL

Novo Nordisk Investigational Site Baltimore, MD

Novo Nordisk Investigational Site Chula Vista, CA

Novo Nordisk Investigational Site Chesterfield, MO

More Trial Locations

Who Is Running the Clinical Trial?

Novo Nordisk A/S Lead Sponsor

References